Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
46 authors.
Xiaohui SunDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0823-0313
Shiv P VermaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3462-4017
Guochong JiaDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-8455-1832
Xinjun WangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5062-4765
Jie PingDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-9907-5819
Xingyi GuoDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-5269-1294
Xiao-Ou ShuDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0711-8314
Jianhong ChenDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-1456-5531
Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2178-8493
Qiuyin CaiDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-9384-5648
Xiaolin LiangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4997-6728
Jirong LongDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-7433-9766
Kenneth OffitClinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2180-2032
Jung H OhDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8791-2755
Anne S ReinerDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1258-6112
Gordon P WattDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2024-0015
Meghan WoodsDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-0514-3938
Yaohua YangDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-3815-7172
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-1717-9943
Stefan AmbsLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-7651-9309
Yu ChenDepartment of Population Health, New York University Grossman School of Medicine, New York, New York.ORCID 0000-0002-1519-4894
Patrick ConcannonDepartment of Pathology, Immunology and Laboratory Medicine, Genetics Institute, University of Florida, Gainesville, Florida.ORCID 0000-0002-5801-1859
Montserrat Garcia-ClosasTrans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0003-1033-2650
Jian GuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3499-0973
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-0097-9971
Jennifer J HuThe University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.ORCID 0000-0002-0021-5699
Dezheng HuoDepartment of Public Health Sciences, University of Chicago, Chicago, Illinois.ORCID 0000-0002-4041-1678
Esther M JohnDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-3259-8003
Julia A KnightProsserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada.ORCID 0000-0002-7610-7635
Christopher I LiDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0003-1543-0743
Charles F LynchDepartment of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa.ORCID 0000-0002-9542-6439
Lene MellemkjærDiet, Cancer and Health, Danish Cancer Institute, Copenhagen, Denmark.ORCID 0000-0001-9222-6215
Katherine L NathansonDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-6740-0901
Barbara NemesureDepartment of Family, Population, and Preventive Medicine, Stony Brook Medicine, Stony Brook, New York.ORCID 0000-0003-4278-9540
Olufunmilayo I OlopadeDepartment of Medicine, University of Chicago, Chicago, Illinois.ORCID 0000-0002-9936-1599
Andrew F OlshanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-9115-5128
Tuya PalDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-8009-2475
Julie R PalmerSlone Epidemiology Center, Boston University, Boston, Massachusetts.ORCID 0000-0002-6534-335X
Michael F PressDepartment of Pathology, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0003-3400-6614
Maureen SandersonDepartment of Family and Community Medicine, Meharry Medical College, Nashville, Tennessee.ORCID 0000-0002-3914-6870
Dale P SandlerEpidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.ORCID 0000-0002-6776-0018
Melissa A TroesterDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-9506-6624
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-1226-070X
Jonine L BernsteinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8634-3837
Matthew F BuasDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8524-3428
Xiang ShuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4129-9403
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
Environmental and Genetic Risk Factors For Breast Cancer: The Sister StudyZIAES044005 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI SANDLER, DALE P · 2009 to 2025
$22.7M
Genome-Wide Association Study of Radiation Exposure and Bilateral Breast CancerR01CA129639 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERNSTEIN, JONINE L. · 2009 to 2013
$15.6M
Breast Cancer genetic study in African-ancestry populationsR01CA202981 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Wei Zheng · 2016 to 2026
$14.1M
BREAST CANCER, RADIATION EXPOSURE, AND THE ATM GENEU01CA083178 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BERNSTEIN, JONINE LISA · 1999 to 2003
$9.3M
Interaction of Radiation, BRCA1/2, and Breast CancerR01CA097397 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BERNSTEIN, JONINE LISA · 2002 to 2006
$4.1M
Integrating genomic and transcriptomic data to identify breast cancer susceptibility genesR01CA235553 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LONG, JIRONG, ZHENG, WEI · 2019 to 2024
$3.3M
Genetic susceptibility to Barrett's esophagus: From GWAS to biologyR01DK128615 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI BUAS, MATTHEW FRANK, YAN, LI · 2022 to 2025
$3.1M
Uncovering Roles of Metabolites in Colorectal Cancer EtiologyR00CA230205 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHU, XIANG · 2020 to 2022
$888k
Radiotherapy-associated breast cancer: machine learning on genotypes to predict individualized riskR21CA234752 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERNSTEIN, JONINE L., OH, JUNG HUN · 2020 to 2021
$462k
National Cancer Institute (NCI) P30CA008748National Cancer Institute (NCI) R00CA230205National Cancer Institute (NCI) R01CA202981National Cancer Institute (NCI) R01CA235553National Cancer Institute (NCI) R21CA234752National Cancer Institute (NCI)) U01CA083178National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK128615NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA086862NCI NIH HHS R00 CA230205NCI NIH HHS R01 CA097397NCI NIH HHS R01 CA129639NCI NIH HHS R01 CA202981NCI NIH HHS R01 CA235553NCI NIH HHS R21 CA234752NCI NIH HHS U01 CA083178NIDDK NIH HHS R01 DK128615NIEHS NIH HHS P30 ES010126
6 · The paper itself
Abstract
Breast cancer includes several subtypes with distinct characteristic biological, pathologic, and clinical features. Elucidating subtype-specific genetic etiology could provide insights into the heterogeneity of breast cancer to facilitate the development of improved prevention and treatment approaches. In this study, we conducted pairwise case-case comparisons among five breast cancer subtypes by applying a case-case genome-wide association study (CC-GWAS) approach to summary statistics data of the Breast Cancer Association Consortium. The approach identified 13 statistically significant loci and eight suggestive loci, the majority of which were identified from comparisons between triple-negative breast cancer (TNBC) and luminal A breast cancer. Associations of lead variants in 12 loci remained statistically significant after accounting for previously reported breast cancer susceptibility variants, among which, two were genome-wide significant. Fine mapping implicated putative functional/causal variants and risk genes at several loci, e.g., 3q26.31/TNFSF10, 8q22.3/NACAP1/GRHL2, and 8q23.3/LINC00536/TRPS1, for TNBC as compared with luminal cancer. Functional investigation further identified rs16867605 at 8q22.3 as a SNP that modulates the enhancer activity of GRHL2. Subtype-informative polygenic risk scores (PRS) were derived, and patients with a high subtype-informative PRS had an up to two-fold increased risk of being diagnosed with TNBC instead of luminal cancers. The CC-GWAS PRS remained statistically significant after adjusting for TNBC PRS derived from traditional case-control GWAS in The Cancer Genome Atlas and the African Ancestry Breast Cancer Genetic Consortium. The CC-GWAS PRS was also associated with overall survival and disease-specific survival among patients with breast cancer. Overall, these findings have advanced our understanding of the genetic etiology of breast cancer subtypes, particularly for TNBC. Significance: The discovery of subtype-informative genetic risk variants for breast cancer advances our understanding of the etiologic heterogeneity of breast cancer, which could accelerate the identification of targets and personalized strategies for prevention and treatment.
Indexed as
Breast NeoplasmsGenetic Predisposition to DiseaseGenome-Wide Association StudyPolymorphism, Single NucleotideCase-Control StudiesFemaleHumansRisk FactorsTriple Negative Breast Neoplasms
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer. · full record | OpenQuestion